The streptococcal agent OK-432 has been used for immunotherapy of head and neck cancer, among other malignancies, but its mechanism of action is unknown. Because the Toll-like receptor 4 (TLR4)/MD-2 complex is important in enabling the mammalian immune system to recognize bacterial components, we investigated whether expression of the TLR4 and MD-2 genes is associated with OK-432-induced anticancer immunity. 
OK-432, a penicillin-killed and lyophilized preparation of a low-virulence strain of Streptococcus pyogenes (group A) (1), has been successfully used as an immunotherapeutic agent in many types of malignancies, including head and neck cancer (2) (3) (4) (5) (6) . We have also reported that OK-432-based immunotherapy has a marked therapeutic effect in patients with oral squamous cell carcinoma (7, 8) . OK-432 elicits antitumor effects by stimulating immunocompetent cells such as macrophages, T cells, and natural killer (NK) cells, and by inducing multiple cytokines including interleukin 1 (IL-1), IL-2, IL-6, tumor necrosis factor-␣ (TNF-␣), and interferon-gamma (IFN-␥) (9) (10) (11) . In addition, OK-432 induces IL-12 and polarizes the T-cell response to a helper T-cell 1 (Th1) dominant state (12) .
Despite the diverse immune effects and encouraging clinical results (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , not all patients respond to OK-432 therapy. Two trials were undertaken to discriminate between those who respond to OK-432 and those who do not: one trial evaluated a skin test with a polysaccharide fraction of OK-432 (13) , and the other evaluated the relationship between T-cell receptor expression and OK-432 responsiveness (14) . However, no definitive methodology has been established to predict patient responsiveness. In part, this may be associated with limited progress made in elucidating the molecular mechanism of action of OK-432, i.e., the identification of effective component(s) of OK-432, and their molecular target(s), such as receptors or signal transducers in immunocompetent cells.
One component of OK-432 that appears to be important in the antitumor effect is a lipoteichoic acid (LTA)-related molecule, OK-PSA (15, 16) . OK-PSA was isolated from a butanol extract of OK-432 by using a cyanogen bromide (CNBr)-activated Sepharose 4B affinity column (Amersham Pharmacia Biotech AB, Uppsala, Sweden) bound with the monoclonal antibody TS-2, which neutralizes the IFN-␥-inducing activity of OK-432 (15, 16) . OK-PSA is a more potent inducer of Th1 cytokines and killer cell activities from human peripheral blood mononuclear cells (PBMCs) than OK-432 and has a marked antitumor activity in tumor-bearing mice (15, (17) (18) (19) (20) . Furthermore, we recently showed that, in mice, OK-PSA elicits cytokine-inducing and antitumor activities via Toll-like receptor 4 (TLR4) signaling (21) , a finding which may help clarify the molecular mechanism of the OK-432-induced antitumor host responses.
TLRs are transmembrane proteins that belong to a newly recognized family of vertebrate pattern recognition receptors within the innate immune system (22, 23) . Subsequent to ligand binding, TLRs initiate signaling through the sequential recruitment of myeloid differentiation protein 88, IL-1R-associated kinase, and TNFR-associated factor 6, which in turn activate downstream mediators such as mitogen-activated protein kinases and nuclear factor-B (NF-B) (24, 25) . Among the 10 identified TLRs, TLR2 and TLR4 recognize gram-positive and gram-negative bacterial cell wall components, including lipopolysaccharide (LPS), LTA, lipoprotein, peptidoglycan (PGN), and lipoarabinomannan (26) (27) (28) (29) (30) (31) . TLR9 recognizes bacterial unmethylated CpG DNA and is the receptor that distinguishes bacterial DNA from self-DNA (32) . It has also been reported that MD-2 (33) and CD14 (34) act as important cofactors in TLR signaling. In particular, MD-2 physically associates with TLR4 on the cell surface, and the TLR4/MD-2 complex confers responsiveness to bacterial components (33) .
Because OK-432 is a bacterial preparation containing multiple components, including OK-PSA, PGN, and unmethylated CpG DNA, it may be possible that signaling via TLRs and their cofactors is involved in OK-432-induced anticancer immunity. In the current study, we examined the relationship between the expression of TLRs and response to OK-432, as indicated by changes in IFN-␥ levels, in patients with head and neck cancer to identify target molecule(s) for OK-432-based immunotherapy.
PATIENTS AND METHODS

Preparation of OK-PSA
OK-PSA was prepared from OK-432 (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) as described (15) . The OK-PSA preparation was tested for LPS contamination by using the Endospecy ES-50M set (Seikagaku Kogyo, Tokyo, Japan), according to the manufacturer's recommended protocol. LPS concentrations in samples were calculated from a standard curve of known LPS concentrations (derived from a solution of Escherichia coli 0111:B4 endotoxin in distilled water) plotted against absorbance at 545 nm (35) .
Patients
This study was carried out in accordance with the standards of our Institutional Committee for the Protection of Human Subjects. Written informed consent was obtained from all patients, and the collection of the samples was approved by the Institutional Review Board. From October 1996 through September 2001, 28 patients (19 male and nine female) with head and neck cancer were treated with OK-432 (Chugai Pharmaceutical Co., Ltd.) at the Second Department of Oral and Maxillofacial Surgery, The Hospital of Tokushima University School of Dentistry. The median patient age was 64 years (range ‫ס‬ 36-77 years). On the basis of the Tumor-Node-Metastasis system for the classification of malignant diseases (36) , there were 17 T2 cancers, seven T3 cancers, four T4 cancers, 15 N0 cancers, 12 N1 cancers, and one N3 cancer. All cancers were M0. There were 27 squamous cell carcinomas and one mucoepidermoid carcinoma. Primary sites of the tumors were tongue (n ‫ס‬ 11), upper alveolus and gingiva (n ‫ס‬ 7), lower alveolus and gingiva (n ‫ס‬ 3), buccal mucosa (n ‫ס‬ 2), floor of the mouth, hard palate, maxillary sinus, parotid gland, and oropharynx (each n ‫ס‬ 1) ( Table 1 ). All of the patients had primary disease and had not received any previous treatment. None of the patients were severely immunodeficient, as determined from clinical examinations.
Protocol for Clinical Study
Within 1 week of diagnosis, patients were enrolled in the study to receive OK-432 as part of a regimen for the treatment of head and neck cancer. The regimen included treatment with OK-432 administered peritumorally or intradermally at a dose of 0.5 Klinische Einheit (KE), i.e., 50 g/week. The dose was increased to 5 KE/week. Patients were monitored for general symptoms related to OK-432 therapy, such as increased fever and/or fatigue. All patients received therapy with OK-432 and UFT, an oral fluoropyrimidine formulation combining tegafur and uracil in a 1 : 4 ratio (Taiho Pharmaceutical Co., Tokyo, Japan), in combination with radiation therapy.
Two blood samples were collected from each patient 5 hours before receiving the first injection of OK-432. From one sample, PBMCs were prepared by the standard Ficoll-Hypaque gradient density centrifugation method (37) . From the other sample, serum was isolated and immediately frozen at −80°C until assayed for IFN-␥ levels. Twenty-four hours after patients received an injection of OK-432, an additional blood sample was collected and the serum was isolated and frozen until assayed for IFN-␥ levels. Within 3 days of collection, all sera were assayed for IFN-␥ levels with an enzyme-linked immunosorbent assay (ELISA) at the Otsuka Assay Laboratory (Tokushima, Japan). The ELISA performed has a lower limit of sensitivity of 7.8 pg/mL for detecting human IFN-␥. /mL) were cultured in RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) (BioWhittaker, Walkersville, MD) in the presence or absence of OK-432 (0.1 KE, i.e., 10 g/mL] or OK-PSA (10 g/mL) for 24 hours. In some experiments, polymyxin B (25 g/mL; Sigma Chemical Co., St. Louis, MO) was added to cultures treated with OK-PSA, and in other experiments, LPS (derived from E. coli 055:B5; Sigma Chemical Co.), with or without polymyxin B, was added to untreated cultures.
In Vitro
RNA Extraction and Semiquantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
After 24 hours, total RNA was extracted from the PBMC cultures by a modified acid-guanidinium-thiocyanate-phenolchloroform method (38) using ISOGEN RNA extracting mixture (Nippon Gene, Toyama, Japan), according to the manufacturer's recommendations. Expression of mRNAs for IFN-␥, TLR2, TLR4, TLR9, MD-2, CD14, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping gene that was used as an internal control, was detected by the semiquantitative RT-PCR. First, 1 g of total RNA was reverse-transcribed using Moloney murine leukemia virus reverse transcriptase (Life Technologies Inc., Gaithersburg, MD) and random primers (Life Technologies Inc.) in a volume of 20 L at 42°C for 60 minutes. Next, 2 L of the reverse-transcribed mixture was subjected to PCR (10 mM Tris-HCl [pH 8.3]; 50 mM KCl; 1.5 mM MgCl 2 ; 0.01% gelatin; dATP, dGTP, dTTP, and dCTP, each at 20 mM), 0.5 U Taq polymerase (Takara Bio Inc., Otsu, Japan), and 0.25 pmol of each primer in a total volume of 20 L. This study used the primer sequences 5Ј-GCCAAAGTCTTGATTGATTGG-3Ј as an upstream primer and 5Ј-TTGAAGTTCTCCAGCTCCTG-3Ј as a downstream primer for TLR2, which yield a 394-base pair (bp) fragment (39); 5Ј-TGGATACGTTTCCTTATAAG-3Ј as an upstream primer and 5Ј-GAAATGGAGGCACCCCTTC-3Ј as a downstream primer for TLR4, which yield a 506-bp fragment (39); 5Ј-GTGCCCCACTTCTCC-3Ј as an upstream primer and 5Ј-GGCACAGTCATGATGTTGTTG-3Ј as a downstream primer for TLR9, which yield a 270-bp fragment (40); 5Ј-GAATTCATGTTACCATTTCTGTTT-3Ј as an upstream primer and 5Ј-GAATTCTAATTTGAATTAGGTTGG-3Ј as a downstream primer for MD-2, which yield a 493-bp fragment (33); 5Ј-GCAGCCTCCTCCTTGTCGCTACC-3Ј as an upstream primer and 5Ј-TCAGGGCCTGCATCAGCTCATCAA-3Ј as a downstream primer for CD14, which yield a 450-bp fragment (41); 5Ј-TGCAGGTCATTCAGATGTAG-3Ј as an upstream primer and 5Ј-AGCCATCACTTGGATGAGTT-3Ј as a downstream primer for IFN-␥, which yield a 306-bp fragment (42) ; and 5Ј-GAAATCCCAGCACCATCTCCAGG-3Ј as an upstream primer and 5Ј-GTGGTGGACCTCATGGCCCAC-CATG-3Ј as a downstream primer for GAPDH, which yield a 781-bp fragment (43) . To amplify the fragments, 25, 28, or 30 PCR cycles were used, with each cycle consisting of 94°C for 60 seconds, 55°C for 90 seconds, and 72°C for 150 seconds, with an initial denaturation step of 94°C for 5 minutes and a final elongation step of 72°C for 5 minutes. PCR was carried out in a DNA Thermal Cycler (Takara Bio Inc.). Amplified complementary DNA (cDNA) was electrophoresed through 1.5% agarose gels containing 100 ng/mL ethidium bromide. After elec- (36) . SCC ‫ס‬ squamous cell carcinoma; TLR ‫ס‬ Toll-like receptor; IFN-␥ ‫ס‬ interferon gamma; RT-PCR ‫ס‬ reverse transcription-polymerase chain reaction; PBMC ‫ס‬ peripheral blood mononuclear cells; ND ‫ס‬ not detected (<7.8 pg/mL).
†Expression of IFN-␥ messenger RNA (mRNA) from patient-derived PBMC treated with OK-PSA in vitro. ‡Expression of IFN-␥ mRNA from patient-derived PBMC treated with OK-432 in vitro. §Amounts of IFN-␥ protein in the sera of patients 24 hours after receiving OK-432. mRNA expression was assessed by RT-PCR. Each RT-PCR product was quantified by densitometry and expressed as a ratio to the relative density (RD) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). − ‫ס‬ an RD ratio of <0.1; ± ‫ס‬ an RD ratio of equal to or greater than 0.1 but less than 0.5; + ‫ס‬ an RD ratio of greater than or equal to 0.5. trophoresis, gels were illuminated with ultraviolet light, viewed, and photographed (Polaroid type 667 film; Polaroid Corp., Cambridge, MA). Densitometric analysis for the RT-PCR band patterns was done by using NIH Image 1.59 software (National Institutes of Health, Bethesda, MD). The relative density (RD) of each specific RT-PCR band was expressed as a ratio to the density of GAPDH, with negative expression defined as RD less than 0.1, marginal expression defined as RD equal to or more than 0.1 but less than 0.5, positive expression defined as RD equal to or greater than 0.5. The identification of each amplified product was confirmed by automated DNA sequencing.
To determine the optimal condition for the semiquantitative RT-PCR described above, we reverse transcribed 0.1, 0.5, 1, and 5 g of total RNA and, using identical PCR conditions, amplified the fragments with different numbers of PCR cycles (from 18 to 40). We decided to use 1 g of total RNA as a template for RT and to use 25 cycles of PCR amplification for GAPDH, 28 cycles for TLR4, and 30 cycles for the other factors.
Established Cell Lines and Culture Media
The derivation of the IL-3-dependent mouse proB cell line Ba/F3 stably expressing human TLR2 (Ba/hTLR2), mouse TLR2 (Ba/mTLR2), human TLR4 (Ba/hTLR4), human TLR4 and human MD-2 (Ba/hTLR4/hMD-2), mouse TLR4 (Ba/ mTLR4), and mouse TLR4 and mouse MD-2 (Ba/mTLR4/ mMD-2) have been described elsewhere (33, 44, 45) . All of the transfectants have also been transfected with p55IgLuc, an NF-B reporter construct (33, 44, 45) . The construct p55IgLuc contains the NF-B p55 regulatory sequence from the immunoglobulin (Ig) kappa light chain promoter upstream of a Photonius pyralis luciferase gene. The construct is used as a measure of NF-B activity. A control cell line that stably expressed only p55IgLuc (Ba/B) was also established. Parental Ba/F3 cells do not express TLR2, TLR4, or MD-2 (33) .
The transfectants were grown in RPMI-1640 medium (Life Technologies Inc.) containing 10% heat-inactivated FBS and 100 U/mL of mouse IL-3. LL/2, a Lewis lung carcinoma cell line, was obtained from American Type Culture Collection (Manassas, VA) and grown in Eagle's minimum essential medium (Life Technologies Inc.) supplemented with 10% FBS. All cell lines were grown in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
Luciferase Assay
The stable transfectants expressing human or mouse TLRs and p55IgLuc were seeded at 5 × 10 5 cells per well into each well of a 48-well dish (Corning Inc., Vernon, NY), and then 1 or 10 g/mL of OK-PSA, OK-432, LPS (derived from E. coli 055:B5; Sigma Chemical Co.), or PGN (Fluka 77140; Sigma Chemical Co.) was added. After 5 hours at 37°C, the cells were harvested and lysed in 100 L of Luciferase Cell Culture Lysis Reagent (Promega, Madison, WI). Luciferase activity was measured using 20 L of lysate and 100 L of Luciferase Assay Substrate (Promega). The luminescence was quantified in relative light units (RLU) by a luminometer (Bio-Orbit, Turku, Finland). Relative luciferase activity was obtained by dividing the RLU value for each treated sample with the RLU value of each untreated sample. The experiment was repeated three times. A 5-hour incubation period was chosen on the basis of our previous studies [Okamoto M, Sato M: unpublished observations and (33, 44, 45) ].
Animals and In Vivo Experiments
All mice were maintained according to the National Institutes of Health standards established in the Guidelines for the Care and Use of Laboratory Animals (http://oacu.od.nih.gov/regs/ guide/guide2.htm), and all experimental protocols were approved by the Animal Investigation Committee of Tokushima University, Tokushima, Japan. C57BL/6 mice deficient in TLR2 (TLR2 −/− ) or in TLR4 (TLR4 −/− ) were previously generated by gene targeting (30, 46) . C57BL/6 mice that express wildtype TLR2 and TLR4 were purchased from Japan SLC Inc. (Shizuoka, Japan). In total, 71 mice were used for the present study.
To examine the role of TLR4 signaling in in vivo IFN-␥ induction by OK-432, wild-type C57BL/6, TLR2 −/− and TLR4 −/− mice were given a single intraperitoneal injection of 100 g of OK-432. After 6 days, OK-432 (100 g/mouse) or physiologic saline was administered intraperitoneally, and 6 hours later, sera were collected and immediately frozen at −80°C until assayed for IFN-␥ levels. ELISA was performed to determine the IFN-␥ concentration in the sera within 3 days. The antitumor effect of OK-432 was evaluated both in wildtype C57BL/6 and TLR4 −/− mice. Syngeneic LL/2 cells (5 × 10 5 /mouse) were injected subcutaneously into the footpads of the mice (one footpad per mouse). Approximately 7 days after the injection and when tumors were approximately 40 mm 3 in volume, the mice were randomly divided into two groups of eight, with almost equal mean tumor volumes. The mice were given 0.2 mL of physiologic saline or 100 g of OK-432 peritumorally on days 8, 12, 15, 19, and 22. The mice were monitored twice a week, and the tumor volume was estimated by measuring tumor size and using the following formula: tumor
, where L represents the largest diameter and W represents the smallest diameter.
Treatment of Mouse Spleen Cells With Immunomodulators
Spleen cells (2 × 10 6 /mL) were isolated from wild-type C57BL/6, TLR2 −/− , and TLR4 −/− mice as described (47) and treated with OK-PSA (1 or 10 g/mL), OK-432 (1 or 10 g/ mL), LPS (1 or 10 g/mL), or PGN (1 or 10 g/mL). After 48 hours, supernatants were collected and assayed for IFN-␥ by ELISA (BioSource International, Inc., Camarillo, CA).
We also examined the effect of long-term OK-432 treatment of mouse spleen cells on IFN-␥ induction. OK-432 (1 or 10 g/mL) was added to the culture of spleen cells isolated from wild-type or TLR4 −/− mice. Supernatants were collected at 0, 12, 24, 48, 72, 120, and 168 hours after adding OK-432 and immediately frozen at −80°C until they were assayed for IFN-␥. All ELISAs were performed within 3 days of collecting the supernatants.
Statistical Analysis
The relationship between the TLR expression and IFN-␥ induction by OK-432 or OK-PSA was statistically evaluated by a two-sided Fisher's exact test. In animal experiments, results were expressed as means with 95% confidence intervals (CIs). Comparisons between groups were made using Student's twotailed t test. Values of P<.05 were considered statistically sig-
RESULTS
Effect of Polymyxin B on OK-PSA-Induced IFN-␥ Production
To determine whether the IFN-␥-inducing activity of OK-PSA was the result of endotoxin contaminating the OK-PSA preparation, we examined the effect of polymyxin B, an LPS inhibitor, on OK-PSA-induced IFN-␥ production from PBMCs derived from healthy volunteers. IFN-␥ production induced by OK-PSA was not inhibited by the addition of 25 g/mL of polymyxin B, whereas IFN-␥ production induced by LPS was almost completely neutralized by polymyxin B (data not shown). These results suggest that IFN-␥-inducing activity of OK-PSA was not the result of endotoxin contaminating the OK-PSA preparation.
Expression of mRNAs for TLRs and Their Cofactors in PBMCs Derived From Patients With Head and Neck Cancer
To identify the target molecule(s) for OK-432-based immunotherapy, we first examined the expression of TLR2, TLR4, TLR9, MD-2, and CD14 by RT-PCR analysis in PBMCs from 28 patients with head and neck cancer. We defined levels of expression on the basis of calculated relative signal intensities. Of 28 patients, 27 (96.4%) patients expressed TLR2 mRNA and one (3.6%) patient marginally expressed TLR2 mRNA; 26 (92.9%) patients expressed TLR4 mRNA and two (7.1%) patients did not; 26 (92.9%) patients expressed TLR9 mRNA and two (7.1%) patients did not; 22 (78.6%) patients expressed MD-2 mRNA and six (21.4%) patients did not. All patients expressed CD14 mRNA. Twenty (71.4%) patients expressed mRNA for TLR4 and MD-2 (Fig. 1 , A, and Table 1 ). Fig. 1 . Expression of Toll-like receptors (TLRs), MD-2, and CD14, and interferon-gamma (IFN-␥) in head and neck cancer patients. Total RNAs were extracted from the peripheral blood mononuclear cells (PBMCs) isolated from 28 patients with head and neck cancer, and expression of mRNAs for TLR2, TLR4, TLR9, MD-2, CD14, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). RT-PCR products were separated by electrophoresis and visualized by staining with ethidium bromide (A). Patient-derived PBMCs (1 × 10 6 / mL) were stimulated with 10 g/mL of OK-432 (B) or OK-PSA (C) for 24 hours. Total RNAs were extracted, and expression of IFN-␥ and GAPDH messenger RNAs (mRNAs) were analyzed by RT-PCR. Sera were collected from patients with head and neck cancer 24 hours after they received a peritumoral or intradermal injection of OK-432. IFN-␥ levels in the sera were measured with a specific enzyme-linked immunoassay (ELISA) (D). In A, B, and C, positive controls (P) for the RT-PCR used total RNAs from Ba/F3 cells transfected with the expression plasmid containing each complementary DNA (cDNA) for human TLRs, MD-2, CD14, or IFN-␥. PCRs done without reverse transcription mixture were used as negative controls.
Effect of OK-432 and OK-PSA on IFN-␥ Induction From Patient-Derived PBMCs
To determine the effect of OK-432 and OK-PSA on IFN-␥ induction, patient-derived PBMCs were treated with OK-432 or OK-PSA for 24 hours, and the expression of IFN-␥ mRNA was then analyzed by RT-PCR. Expression of IFN-␥ mRNA was not detected or was only faintly detected (RD<0.1) in untreated PBMCs derived from all patients (data not shown). Expression of IFN-␥ mRNA was observed in OK-432-treated PBMCs from all patients (Fig. 1, B , and Table 1 ). By contrast, expression of IFN-␥ mRNA was detected in OK-PSA-treated PBMCs from 19 (67.9%) patients but not from nine (32.1%) patients (Fig. 1, C , and Table 1 ).
All 28 patients were administered OK-432 as a cancer immunotherapy. We measured IFN-␥ levels in sera collected from the patients 5 hours before and 24 hours after OK-432 administration. Serum IFN-␥ protein was not detectable (i.e., was <7.8 pg/mL) in any of the patients before OK-432 treatment (data not shown). Twenty-four hours after OK-432 injection, IFN-␥ protein levels in the sera were detectable in 21 (75%) patients (Fig.  1 , D, and Table 1 ).
Relationship Between Expression of TLR Genes and IFN-␥ Induction by OK-PSA or OK-432
We next statistically analyzed the relationship between TLR expression and IFN-␥ induction by OK-PSA or OK-432 with the two-sided Fisher's exact test. In in vitro experiments with patient-derived PBMCs, OK-PSA increased the expression of IFN-␥ mRNA in 19 of 20 (95%) patients who expressed both TLR4 and MD-2 mRNA. Moreover, OK-PSA did not induce IFN-␥ mRNA expression in all eight of eight (100%) patients who did not express TLR4 or MD-2 mRNA. There was a statistically significant relationship between TLR4 and MD-2 mRNA expression and IFN-␥ induction by OK-PSA (P<.001) ( Table 2 ), suggesting that IFN-␥ induction by OK-PSA requires the TLR4/MD-2 complex. By contrast, IFN-␥ mRNA expression induced by OK-432 was observed in all patients, which indicated that there was no statistically significant relationship between TLR4 and MD-2 expression and IFN-␥ induction by OK-432. No statistically significant relationship was observed between TLR2, TLR9, or CD14 mRNA expression and OK-432-or OK-PSA-induced IFN-␥ mRNA expression.
We detected a statistically significant relationship between increased IFN-␥ protein levels in the sera of patients administered OK-432 and expression of TLR4 and MD-2 genes (P<.001, Table 3 ). An increase in serum IFN-␥ protein in response to OK-432 was detected in 19 of 20 (95%) patients who expressed TLR4 and MD-2 mRNAs. Serum IFN-␥ protein was not detected after OK-432 administration in six of eight (75%) patients who did not express TLR4 or MD-2 mRNAs. No relationship was observed between IFN-␥ induction and TLR2 (P>.999), TLR9 (P>.999), or CD14 (P>.999) expression. Both TLR4 and MD-2 were apparently required for IFN-␥ induction by OK-432 in patients with head and neck cancer, a result that was similar to the results from the in vitro study in which the PBMCs were stimulated to express IFN-␥ with OK-PSA but not with OK-432.
Clinical Outcome of Patients Treated With OK-432 and UFT in Combination With Radiotherapy
All of the patients examined in the current study received OK-432 therapy with UFT in combination with radiotherapy. Ten of the 20 patients (50%) who expressed TLR4 mRNA and MD-2 mRNA became histopathologically tumor-free after therapy, without surgical resection. By contrast, all eight patients who did not express TLR4 mRNA or MD-2 mRNA became tumor-free only after having their tumors surgically resected after therapy (Table 1) .
Relationship Between Expression of TLRs and IFN-␥ Induction in PBMCs Derived From Healthy Volunteers
To examine the relationship between TLR mRNA expression and IFN-␥ induction in healthy donors, we screened healthy donor-derived PBMCs for responsiveness to OK-432 or OK-PSA. In vitro experiments were done using PBMCs from eight healthy donors. Seven donors expressed TLR2 mRNA, and one donor marginally expressed TLR2 mRNA. Six donors expressed TLR9 mRNA, one donor marginally expressed TLR9 mRNA, and one donor did not express TLR9 mRNA. All donors expressed TLR4, MD-2, and CD14 mRNAs. After in vitro treat- †Expression of IFN-␥ messenger RNA (mRNA) or TLR4 or MD-2 mRNA from patient-derived PBMCs treated with OK-PSA (10 g/mL) in vitro for 24 hours. mRNA expression was determined by reverse transcription-polymerase chain reaction (RT-PCR). The relative density (RD) of each PCR product was compared with that of a control mRNA (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]), and a ratio of the RDs was used to quantify expression levels. Positive ‫ס‬ an RD ratio of equal to or greater than 0.5; negative ‫ס‬ an RD ratio of less than 0.1. †IFN-␥ protein detected by an enzyme-linked immunosorbent assay in patient sera 24 hours after receiving OK-432. + ‫ס‬ IFN-␥ protein levels higher than 7.8 pg/mL; − ‫ס‬ IFN-␥ protein levels lower than 7.8 pg/mL. ‡mRNA expression was determined by reverse transcription-polymerase chain reaction (RT-PCR). The relative density (RD) of each PCR product was compared to that of a control mRNA (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]), and a ratio of the RDs was used to quantify expression levels. Positive ‫ס‬ an RD ratio of equal to or greater than 0.5; negative ‫ס‬ an RD ratio of less than 0.1. ment with OK-432 or OK-PSA, PBMCs from all donors expressed IFN-␥ mRNA. Thus, the relationship between IFN-␥ induction and expression of TLR4, MD-2, and CD14 genes could not be assessed from these donors. No clear relationship between the expression of TLR2 and TLR9 genes and IFN-␥ expression was observed (P>.999) (data not shown).
Effect of OK-432 and OK-PSA on TLR4-Mediated NF-B Activation
The data strongly suggested that TLR4/MD-2 signaling is closely associated with OK-432-mediated IFN-␥ induction in vivo, but not in vitro, and OK-PSA-mediated IFN-␥ induction in vitro. To test the hypothesis that TLR4/MD-2 signaling was directly associated with IFN-␥ induction, we next examined TLR4/MD-2 downstream signaling events in response to treatment with OK-432 and OK-PSA.
TLR-mediated signaling activates the transcription factor NF-B (24, 25) . We examined whether an NF-B-dependent reporter construct could be activated in response to OK-432 and OK-PSA signals mediated through the TLR4/MD-2 complex. We examined the responsiveness of Ba/F3 transfectants that stably express human TLR2 (Ba/hTLR2), mouse TLR2 (Ba/ mTLR2), human TLR4 (Ba/hTLR4), human TLR4 and human MD-2 (Ba/hTLR4/hMD-2), mouse TLR4 (Ba/mTLR4), or mouse TLR4 and mouse MD-2 (Ba/mTLR4/mMD-2) to OK-432 and OK-PSA. Ba/F3 transfectants were cultured for 5 hours in the presence of OK-432, OK-PSA, LPS, or PGN (Fig. 2) . Compared with control cells that did not express any TLR, OK-PSA dosedependently induced NF-B activation in Ba/hTLR4 (2.1-fold increase in NF-B activity by 1 g/mL of OK-PSA and 9.0-fold increase by 10 g/mL of OK-PSA), Ba/mTLR4 (10.4-fold increase in NF-B activity by 1 g/mL of OK-PSA and 16.5-fold increase by 10 g/mL of OK-PSA), Ba/hTLR4/hMD-2 (5.5-fold increase in NF-B activity by 1 g/mL of OK-PSA and 16.4-fold increase by 10 g/mL of OK-PSA), and Ba/mTLR4/ mMD-2 cells (20.9-fold increase in NF-B activity by 1 g/mL of OK-PSA and 27.4-fold increase by 10 g/mL of OK-PSA). OK-432 did not induce NF-B activation in any of the transfectants tested. Compared with control cells that did not express any TLR, LPS induced NF-B activation in cells that expressed TLR4 (Ba/hTLR4, Ba/mTLR4, Ba/hTLR4/hMD-2, and Ba/ mTLR4/mMD-2), and PGN induced NF-B activation in cells that expressed TLR2 (Ba/hTLR2 and Ba/mTLR2) but not in cells that expressed TLR4. The data from the experiments using LPS and PGN were consistent with previous reports (28, 30) .
Effect of OK-432 or OK-PSA on IFN-␥ Induction In Vitro
To examine the role of TLR4 on IFN-␥ induction by OK-432 or OK-PSA, mouse splenocytes from C57BL/6 mice that express wild-type TLR4 and TLR2 genes or from various TLR knockout mice were cultured in the presence of OK-432 or OK-PSA for 24 hours, and the supernatants were analyzed for IFN-␥ protein. Untreated splenocytes derived from wild-type C57BL/6, TLR2 −/− , or TLR4 −/− mice did not secrete IFN-␥. OK-432 induced IFN-␥ from splenocytes derived from C57BL/6 mice that express the wild-type TLR4 gene and from TLR2 −/− mice (Fig. 3, A) . OK-432 also induced IFN-␥ from splenocytes derived from TLR4 −/− mice (Fig. 3, A) . Although OK-PSA induced IFN-␥ from splenocytes derived from C57BL/6 mice and TLR2 −/− mice, it did not induce IFN-␥ from splenocytes derived from TLR4 −/− mice. LPS induced IFN-␥ from splenocytes derived from C57BL/6 mice and TLR2 −/− mice but not from TLR4 −/− mice. PGN induced IFN-␥ from splenocytes derived from C57BL/6 and TLR4 −/− mice but not from TLR2 −/− mice (Fig. 3, A) .
We next examined the effect of long-term OK-432 treatment on changes in IFN-␥ production from mouse splenocytes. Splenocytes derived from wild-type mice and TLR4 −/− mice were stimulated with 0.1 g/mL of OK-432 for 7 days, and IFN-␥ levels in the supernatants were measured at regular intervals. After 24 hours, OK-432 had induced comparable levels of IFN-␥ in the splenocyte cultures derived from wild-type mice and from TLR4 −/− mice. However, the IFN-␥ levels in supernatants from splenocytes derived from wild-type mice continued to increase over time, whereas those in supernatants from splenocytes derived from TLR4 −/− mice peaked at 120 hours and declined thereafter. The maximal level of IFN-␥ detected in cultures derived from TLR4 −/− mice was 625 pg/mL (95% CI ‫ס‬ 567 to 683 pg/mL), which was statistically significantly lower than the 965 pg/mL (95% CI ‫ס‬ 923 to 1007 pg/mL) detected in cultures from wild-type mice (P ‫ס‬ .005) (Fig. 3, B) .
Effect of OK-432 on IFN-␥ Induction In Vivo in TLR4 −/− Mice
We examined the role of TLR4 signaling in in vivo IFN-␥ induction by OK-432. Wild-type C57BL/6 and TLR4 −/− mice were given an injection of OK-432, and 6 days later, they were given a second injection of OK-432. Six hours after the second injection, serum IFN-␥ levels were measured. IFN-␥ was not detected in the sera derived from any mice treated with physiologic saline (Fig. 4) . Compared with mice who received only saline, serum IFN-␥ levels were statistically significantly increased to 553 pg/mL (95% CI ‫ס‬ 496 to 610 pg/mL) in wildtype C57BL/6 and to 426 pg/mL (95% CI ‫ס‬ 400 to 452 pg/mL) in TLR2 −/− mice after OK-432 administration, but to only 29.6 pg/mL (95% CI ‫ס‬ 23.9 to 35.3 pg/mL) in the sera from TLR4 −/− −/− mice were statistically significantly lower at 48 hours (P ‫ס‬ .027), at 72 hours (P ‫ס‬ .008), at 120 hours (P ‫ס‬ .006), and at 168 hours (P ‫ס‬ .002).
mice after OK-432 administration (Fig. 4) . The serum IFN-␥ level in any nonprimed mouse did not increase after OK-432 administration (data not shown).
Effect of OK-432 in Tumor-Bearing TLR4 −/− Mice
Finally, we compared the effect of OK-432 in wild-type C57BL/6 and TLR4 −/− mice with syngeneic Lewis lung carcinomas. Twenty-two days after tumor inoculation, the mean tumor volume in wild-type mice that received peritumoral injections of OK-432 was statistically significantly smaller (369 mm 3 , 95% CI ‫ס‬ 293 to 445 mm 3 ) than the mean tumor volume in wild-type mice who received injections of saline (811 mm 3 , 95% CI ‫ס‬ 655 to 967 mm 3 ) (P ‫ס‬ .007) (Fig. 5, A) . By contrast, regardless of treatment, there was no statistically significant difference in mean tumor volumes in TLR4 −/− mice (Fig. 5, B) .
DISCUSSION
IFN-␥, a representative Th1 cytokine, plays an important role in anticancer immunity. It has been reported that IFN-␥ production is associated with a favorable clinical outcome in the patients with several types of malignancies, including colorectal carcinoma and cervical carcinoma (48, 49) . OK-432 augments anticancer host responses by increasing production of Th1 cytokines, especially IFN-␥ (10, 50) . We therefore examined the relationship between the expression of TLRs and response to OK-432, indicated by changes in IFN-␥ levels, in patients with head and neck cancer to identify target molecule(s) for OK-432-based immunotherapy.
We found that responsiveness of patients to OK-432 therapy, as represented by increased serum IFN-␥ level, was statistically significantly related to the expression of TLR4 and MD-2. Because the TLR4/MD-2 complex confers responsiveness to bacterial components (33) , it is suggested that both TLR4 and MD-2 may be required for signaling of OK-432 and for subsequent IFN-␥ production in vivo. Thus, we conclude that expression of both TLR4 and MD-2 may be useful markers to discriminate between responders and nonresponders to OK-432.
It is interesting to note that the results obtained by using patient-derived PBMCs in vitro were different from those results obtained in vivo. Although responsiveness to OK-432 was closely associated with TLR4 and MD-2 expression in vivo, when PBMCs were treated in vitro with OK-432, increased expression of IFN-␥ mRNA was irrespective of the expressed TLR4 and MD-2 phenotype. However, when PBMCs were treated with OK-PSA in vitro, increased expression of IFN-␥ mRNA was dependent on expression of TLR4 and MD-2 −/− mice given OK-432 was statistically significantly lower than that from C57BL/6 wild-type (P ‫ס‬ .003) and from TLR2 −/− mice (P ‫ס‬ .019). ND ‫ס‬ not detected (<7.8 pg/mL). Shaded bars represent OK-432. mRNAs. Thus, in patients with head and neck cancer, the effect of in vivo OK-432 administration was similar to the effect of OK-PSA, but not with OK-432 stimulation in vitro. The discrepancy between OK-432-mediated IFN-␥ induction in vivo and induction in vitro can be at least partially explained by the fact that, in vitro, IFN-␥ induction by OK-432 in splenocytes derived from TLR4 −/− mice was attenuated after 48 hours compared with that in splenocytes derived from wild-type mice. Furthermore, IFN-␥ levels may decrease more rapidly in vivo than in vitro. Thus, IFN-␥ induced by OK-432 not via TLR4 may be difficult to detect in sera, and it may also be hard to elicit an anticancer effect mediated by IFN-␥.
The results from our human studies were consistent with those from our TLR4 −/− mice studies, with an impaired IFN-␥ inducing an antitumor effect of OK-432 observed in TLR4 −/− mice bearing syngeneic carcinomas. From our results we hypothesized that, in both in vivo and in vitro environments, because OK-432 consists of whole bacterial bodies, it is phagocytized by professional phagocytes such as macrophages, dendritic cells, and neutrophils. The phagocytes are then activated, and they release IFN-␥-inducing factors, including IL-12 and IL-18, which stimulate T cells and NK cells to produce IFN-␥. This suggests that OK-432 induces IFN-␥ indirectly and not through a TLR4/MD-2 signal-transducing pathway. The results from the luciferase reporter assay using TLR4-and MD-2-expressing Ba/ F3 cells support this hypothesis, suggesting that OK-432 could not directly induce IFN-␥ without the presence of an additional cell type, most probably phagocytes. Further support for this hypothesis comes from the fact that OK-432 induces maturation of dendritic cells in vitro, not through TLR2 or TLR4 but through ␤2 integrins, which are important molecules used by dendritic cells and macrophages for phagocytizing antigens (51) . In an in vivo environment, macrophages and dendritic cells should be activated by phagocytizing OK-432; however, this activation may be insufficient to increase IFN-␥ levels in the sera of cancer patients and to elicit an antitumor effect in mice in vivo, because OK-432 was not effective in patients who did not express TLR4 or MD-2 mRNAs or in TLR4 −/− mice in vivo. An association between an effective component(s) of OK-432 (e.g., OK-PSA) and TLR4/MD-2 complex may be required to elicit IFN-␥-inducing and antitumor effects. Furthermore, we hypothesized that the effective component(s) may be the molecule(s) that are released after the bacterial bodies are phagocytized and digested. In fact, we detected a soluble antigen recognized by the TS-2 monoclonal antibody (possibly OK-PSA) in culture supernatants derived from splenocytes treated with OK-432 (data not shown). This hypothesis is now under investigation in our laboratory.
In the current study, we observed one patient in whom IFN-␥ was not induced by OK-432 in vivo or by OK-PSA in vitro despite expression of both TLR4 and MD-2. In this patient, we are now investigating possible mutations in the TLR4 and MD-2 genes. Several mutations in human TLR4 genes were observed in endotoxin-hyporesponsive hosts (52) , but there has been no report, to our knowledge, of mutations in the human MD-2 gene. We noted that in two patients who did not express MD-2, IFN-␥ was detected in the sera, although the patient-derived PBMCs showed no response to OK-PSA in vitro. It is possible that, in these patients, another component(s) in addition to OK-PSA may exhibit biologic activity via TLR2 or TLR9 but not via the TLR4/MD-2 complex or that immune cells might be activated more strongly by phagocytizing OK-432 in these patients than in other patients.
Our findings should help identify the molecular mechanism by which OK-432 enhances antitumor immunity, and they suggest that expression of both TLR4 and MD-2 mRNAs may be useful markers to discriminate between patients who may respond and those who will not respond to OK-432-based immunotherapy. In addition, introduction of TLR4 or MD-2 into patients predicted not to respond to recover TLR4/MD-2 signaling may be a potent strategy for improving the response to OK-432 therapy. This hypothesis is now under investigation in an animal study using mice deficient for the TLR4 or MD-2 gene.
